Diagnostic Biosystems (DBS) has launched the Mosaic 360 System with a product offering of novel Multiplex Immunohistochemistry kits and a complementary line of optimized IHC reagents.
The company introduces a portfolio of five Mosaic Multiplex lung cancer kits for use in tissue analysis of suspected lung cancer patients.
Mosaic Multiplex kits will allow testing of multiple analytes on one slide with a complete kit optimized for the DBS Mosaic 360 System automated platform for lab to lab standardized results.
The Mosaic System also includes a new line of plug and play reagents optimized on the Mosaic 360 platform to provide convenience for the Histology Technologist in the Pathology laboratory.
DBS president and CEO said Bipin Gupta the company believes it is important to provide the most information with the limited tissue available in cancer patients.
"Our standardized Mosaic Multiplex lung cancer kits are focused on solving this problem," Gupta added.
